|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012634,
umls-concept:C0026769,
umls-concept:C0036043,
umls-concept:C0205210,
umls-concept:C0441655,
umls-concept:C0751967,
umls-concept:C0936012,
umls-concept:C1172734,
umls-concept:C1280500,
umls-concept:C1514923,
umls-concept:C2603343
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-2-23
|
|
pubmed:abstractText |
The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study has prompted the investigation of whether natalizumab can increase the proportion of patients with relapsing-remitting multiple sclerosis who do not have disease activity.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1474-4422
|
|
pubmed:author |
pubmed-author:BatesDavidD,
pubmed-author:GalettaStevenS,
pubmed-author:GiovannoniGavinG,
pubmed-author:HavrdovaEvaE,
pubmed-author:HutchinsonMichaelM,
pubmed-author:HydeRobertR,
pubmed-author:KimRichardR,
pubmed-author:LublinFred DFD,
pubmed-author:O'ConnorPaul WPW,
pubmed-author:PaceAmyA,
pubmed-author:PhillipsJ TheodoreJT,
pubmed-author:PolmanChris HCH,
pubmed-author:StefoskiDusanD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
254-60
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19201654-Adolescent,
pubmed-meshheading:19201654-Adult,
pubmed-meshheading:19201654-Antibodies, Monoclonal,
pubmed-meshheading:19201654-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19201654-Disability Evaluation,
pubmed-meshheading:19201654-Disease-Free Survival,
pubmed-meshheading:19201654-Double-Blind Method,
pubmed-meshheading:19201654-Female,
pubmed-meshheading:19201654-Gadolinium,
pubmed-meshheading:19201654-Humans,
pubmed-meshheading:19201654-Immunosuppressive Agents,
pubmed-meshheading:19201654-Longitudinal Studies,
pubmed-meshheading:19201654-Magnetic Resonance Imaging,
pubmed-meshheading:19201654-Male,
pubmed-meshheading:19201654-Middle Aged,
pubmed-meshheading:19201654-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:19201654-Odds Ratio,
pubmed-meshheading:19201654-Retrospective Studies,
pubmed-meshheading:19201654-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
|
|
pubmed:affiliation |
Charles University in Prague, Department of Neurology, First Faculty of Medicine, Prague, Czech Republic. eva.havrdova@gmail.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
